Mink Therapeutics

Nov 03, 2022

•

Sep 30, 2022

Mink Therapeutics Q3 2022 Earnings Report

Reported financial results for the third quarter of 2022 and provided a corporate update.

Key Takeaways

MiNK Therapeutics reported a net loss of $6.3 million for the third quarter of 2022, with a cash balance of $24.2 million at the end of the quarter. The company highlighted progress in clinical programs, next-generation pipeline development, and scaling up internal cGMP manufacturing capabilities.

Ended the third quarter 2022 with a cash balance of $24.2 million.

Cash used in operations for the third quarter ended September 30, 2022, was $5.6 million.

Net loss for the quarter ended September 30, 2022, was $6.3 million or $0.19 per share.

Five abstracts accepted for presentation at Society of Cancer Immunotherapy 37th Annual Meeting, November 8th to 12th.

Previous year: -$0.59

-67.8%

Cash and Equivalents

$24.2M